CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 6 incoming connections
- ScaleRevenue is $806.6M, above the global median of $548.88M
- PositionReturn on equity is -32.5%, lower than 95% of its Diagnostics & Research peers (median 1.2%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
398.86MUSDvs all stocks (USD)
Revenue (TTM)
806.60MUSDvs all stocks (USD)
Profit Margin
-13.96%vs Diagnostics & Research peers
Beta
1.68xvs all stocks
52-Week Change
-42.40%vs all stocks
Market Capitalization
398.86MUSDvs all stocks (USD)
Enterprise Value
494.16MUSDvs all stocks (USD)
Forward P/E
-7.28xvs Diagnostics & Research peers
Price to Sales (TTM)
0.4945xvs Diagnostics & Research peers
Price to Book (MRQ)
1.31xvs Diagnostics & Research peers
Enterprise to Revenue
0.6130xvs Diagnostics & Research peers
Enterprise to EBITDA
-12.26xvs Diagnostics & Research peers
Gross Margin
66.60%vs Diagnostics & Research peers
Profit Margin
-13.96%vs Diagnostics & Research peers
Operating Margin
-20.40%vs Diagnostics & Research peers
Return on Assets (TTM)
-8.60%vs Diagnostics & Research peers
Return on Equity (TTM)
-32.54%vs Diagnostics & Research peers
Revenue (TTM)
806.60MUSDvs all stocks (USD)
Revenue per Share (TTM)
8.61USDUpdated Sep 28, 2026Quarterly Revenue Growth
-10.50%vs Diagnostics & Research peers
Gross Profit (TTM)
555.20MUSDvs all stocks (USD)
EBITDA (TTM)
-40.30MUSDvs all stocks (USD)
Net Income (TTM)
-112.60MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-10.51%vs Diagnostics & Research peers
Operating Cash Flow (TTM)
7.70MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
18.19MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Diagnostics & Research peers
Revenue
824.50MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
247.90MUSDFY2025 · Dec 31, 2025Gross Profit
576.60MUSDFY2025 · Dec 31, 2025Operating Income
-67.80MUSDvs all stocks (USD)
Pre-tax Income
-395.10MUSDFY2025 · Dec 31, 2025Income Tax Expense
-29.20MUSDFY2025 · Dec 31, 2025Net Income
-365.90MUSDFY2025 · Dec 31, 2025EBIT
-384.60MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-11.50MUSDFY2025 · Dec 31, 2025Research & Development
106.80MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
537.60MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.80MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
10.50MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.95USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.95USDFY2025 · Dec 31, 2025Basic Shares Outstanding
92.60MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
92.60MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-365.90MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-294.70MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
151.30MUSDFY2025 · Dec 31, 2025Interest Paid
8.40MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-365.90MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
53.70MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-32.40MUSDFY2025 · Dec 31, 2025Stock-based Compensation
35.20MUSDFY2025 · Dec 31, 2025Other Non-cash Items
11.10MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
6.20MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.40MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.20MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
0.00USDFY2025 · Dec 31, 2025Long-term Debt Issuance
165.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-80.70MUSDFY2025 · Dec 31, 2025Other Financing Charges
-23.40MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
60.90MUSDFY2025 · Dec 31, 2025Shares Outstanding
95.60MSharesUpdated Sep 28, 2026Float Shares
79.30MSharesUpdated Sep 28, 2026Shares Short
9.35MSharesUpdated Sep 28, 2026Short Ratio
4.96daysvs all stocks
Short % of Shares Outstanding
10.01%vs all stocks
% Held by Insiders
4.06%vs all stocks
% Held by Institutions
97.10%vs all stocks
Total Cash (MRQ)
115.20MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.20USDUpdated Sep 28, 2026Total Debt (MRQ)
210.50MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.6927xvs Diagnostics & Research peers
Current Ratio (MRQ)
2.21xvs Diagnostics & Research peers
Book Value per Share (MRQ)
3.18USDUpdated Sep 28, 2026Total Assets
706.60MUSDvs all stocks (USD)
Total Current Assets
332.60MUSDFY2025 · Dec 31, 2025Total Liabilities
338.60MUSDFY2025 · Dec 31, 2025Total Non-current Assets
374.00MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
204.80MUSDFY2025 · Dec 31, 2025Total Current Liabilities
133.80MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
149.60MUSDFY2025 · Dec 31, 2025Accounts Receivable
115.30MUSDFY2025 · Dec 31, 2025Inventory
30.60MUSDFY2025 · Dec 31, 2025Accounts Payable
30.00MUSDFY2025 · Dec 31, 2025Short-term Debt
6.90MUSDFY2025 · Dec 31, 2025Long-term Debt
202.90MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.70MUSDFY2025 · Dec 31, 2025Common Stock (Book)
900.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.12BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
368.00MUSDvs all stocks (USD)
52-Week Low
2.74USDUpdated Sep 28, 202652-Week High
8.59USDUpdated Sep 28, 202652-Week Change
-42.40%vs all stocks
Beta
1.68xvs all stocks
50-Day MA
3.82USDUpdated Sep 28, 2026200-Day MA
4.82USDUpdated Sep 28, 2026Avg 10-Day Volume
2.53MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.97MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-1.18USDUpdated Sep 28, 2026Other Income / Expense
-318.60MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -32.5%, lower than 95% of its Diagnostics & Research peers (median 1.2%)Significant
Return on equity: -0.33Industry median: 0.01Industry P5: -0.21Peers compared: 30.00
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.67Profit Margin: -0.14
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 2.21Altman Z-Score: -1.81
Financial Health
Altman Z-Score -1.81: distress zoneCritical
Altman Z-Score: -1.81
Supply Chain
Midstream position: 6 outgoing, 6 incoming connectionsNotable
Outgoing: 6.00Incoming: 6.00
High connectivity hub: 12 industry connectionsNotable
Total Connections: 12.00
Scale
Revenue is $806.6M, above the global median of $548.88MNotable
Revenue (USD): 806,600,000Global Median: 548,883,780.48
Companies that share the same coordination system — how they create, deliver, or capture value.
RattanIndia Power Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Shanghai Carthane Co. Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Ibstock plc
Tier 1ProductionThroughput-Bound ConversionFlowRule
Intermestic Inc.
Tier 1ProductionThroughput-Bound ConversionRule
Arbonia AG
Tier 1ProductionThroughput-Bound ConversionFlowRule
Shandong Yabo Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Deceuninck NV
Tier 1ProductionThroughput-Bound ConversionFlowRule
Kitazato Corporation
Tier 1ProductionThroughput-Bound ConversionRule
Shandong NewJiFeng Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Slavneft-Yaroslavnefteorgsintez Joint Stock Company
Tier 1ProductionThroughput-Bound ConversionFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Md Entertainment Tbk
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Beijing Xiaocheng Technology Co. Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated